Floatz logo

Ontorpacept

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Mayo Clinicprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Yazeed Sawalha
Phase 2B
Inno-206
Rutgers, The State University of New Jersey
Phase 2B
ETOPOSIDE
David Bond, MD
Phase 2B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2B
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2B

View all 39 →

Same molecule, other indications

Ontorpacept is also rated in:

B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
diffuse large B-cell lymphoma with chronic inflammationDormant
CCC
Indicative ·
53 / 100
View asset →
ALK-positive large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →